REG - Adv Medical Solutns. - Director/PDMR Shareholding

Advanced Medical SolutionsAnnouncement

15/05/2025 18:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250515:nRSO9167Ia&default-theme=true

RNS Number : 9167I  Advanced Medical Solutions Grp PLC  15 May 2025

     15 May 2025

            Advanced Medical Solutions Group plc

("AMS", the "Company" or the "Group")

 

            Director/PDMR Shareholding

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the
world-leading specialist in tissue-healing technologies, announces the
following Director share transactions.

 

The Company was notified on 12 May 2025 that on the same day, Individual
Savings Accounts ("ISA's") held in the name of Susan Searle, Non-Executive
Director, purchased 5,000 ordinary shares of 5p each ("Ordinary Shares") at a
price of 194.83p per Ordinary Share and ISA's held by Fraser Searle, husband
and a PCA of Susan Searle, purchased 5,000 Ordinary Shares at a price of
194.83p per Ordinary Share. Following these transactions, Susan Searle and
persons closely associated hold 0.005% of the issued share capital.

 

As part of the Share Incentive Plan ("SIP") and Employee Share Purchase Plan
("ESPP), Executive Directors and employees can sacrifice part of their annual
bonus and/or salary into the SIP and ESPP, which for every share purchased on
behalf of the employee they receive matching shares which are deferred for a
minimum of three years. Chris Meredith (CEO) and Eddie Johnson (CFO) have
elected to sell certain existing shares to use the proceeds to re-invest in
the SIP and ESPP.

 

The Company was notified on 12 May 2025 that following his decision to
participate Chris Meredith, who is a Director and PDMR, executed the exercise
of 64,000 nil-cost options from the existing Long Term Incentive Plan ("LTIP")
and subsequently sold 64,000 Ordinary Shares of 5p each on 12 May 2025 at a
share price of 194.61p per Ordinary Share. The proceeds from the sale of the
shares were used to purchase shares in the SIP and ESPP, as detailed below.

 

The Company was further notified on 12 May 2025 that following his decision to
participate Eddie Johnson, who is a Director and PDMR, executed the exercise
of 28,126 nil-cost options from the existing Long Term Incentive Plan ("LTIP")
and subsequently sold 28,126 Ordinary Shares of 5p each on 12 May 2025 at a
share price of 196.4p per Ordinary Share. The Company was further notified on
13 May 2025 that Eddie Johnson had exercised 16,402 nil-cost Matching Shares
from the ESPP and subsequently sold 16,402 Ordinary Shares of 5p each on 13
May 2025 at a share price of 194.62p per Ordinary Share. The proceeds from the
sale of the shares were used to purchase shares in the SIP and ESPP, as
detailed below.

 

The Trust which manages the SIP and ESPP on behalf of the employees of AMS has
purchased Ordinary Shares of 5p each ("Ordinary Shares") on 12 May 2025, at a
share price of 195.04p on behalf of Chris Meredith (923 Ordinary Shares into
the SIP, 32,168 Ordinary Shares into the ESPP) and Eddie Johnson (923 Ordinary
Shares into the SIP, 20,669 Ordinary Shares into the ESPP), who are both
Directors/PDMRs, as part of the SIP and, under the terms of the SIP and ESPP,
these shares will be held in trust on their behalf. The Company was notified
of the completion of these purchases on 15 May 2025.

 

In addition Chris Meredith and Eddie Johnson further exercised outstanding
nil-cost LTIPs and nil-cost ESPP Matching Shares in order to transfer them
into their own names, selling a proportion to cover tax and National
Insurance.

 

The Company was notified on 12 May 2025 that Chris Meredith exercised 307,210
nil-cost LTIPs and 114,518 nil-cost ESPP Matching Shares and subsequently sold
211,521 Ordinary Shares at a share price of 193.80p per Ordinary Share on 12
May 2025, retaining 210,207 Ordinary Shares in his own name.

 

The Company was notified on 13 May 2025 that Eddie Johnson exercised 130,776
nil-cost LTIPs, 86,184 nil-cost ESPP Matching Shares and 12,737 Deferred Bonus
Shares and subsequently sold 115,206 Ordinary Shares at a share price of
194.62p per Ordinary Shares on 13 May 2025, retaining 114,491 Ordinary Shares
in his own name.

 

The number of shares held by Chris Meredith and Eddie Johnson and their PCAs
will increase their beneficial interest in the Company from the level prior to
these transactions and the beneficial ownership of Chris Meredith and Eddie
Johnson are as follows:

 

 Director/PDMR             Date purchased/ transferred  Shares purchased (through SIP and ESPP)  Shares retained from exercises  Resultant holding  % of issued share capital
 Chris Meredith            12 May 2025                  33,091                                   210,207                         2,045,694          0.94%

 Chief Executive Officer
 Eddie Johnson             12 May 2025 and 13 May 2025  21,592                                   114,491                         313,638            0.14%

 Chief Financial Officer

 

The notification below, made in accordance with the requirements of the EU
Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them

 

 1.  Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name:

     1. Susan Searle

     2. Fraser Searle
 2.  Reason for the notification
 a)  Position/status:

     1. Non-Executive Director

     2. PCA to a Non-Executive Director
 b)  Initial notification/Amendment: Initial Notification
 3.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name:   Advanced Medical Solutions Group plc
 b)  LEI: 213800HJP6OWOSZI1L74
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument: Ordinary Shares
     of 5p

     Identification code: GB0004536594
 b)  Nature of the transactions:

     ·        Purchase of Ordinary Shares into ISAs for a Non-Executive
     Director (Susan Searle)

     ·        Purchase of Ordinary Shares into ISAs for a PCA of a
     Non-Executive Director (Fraser Searle)
 c)  Price(s) and volume(s):

Price(s)                                                                       Volume(s)
     Purchase of Ordinary Shares at 194.83p per share for a Non-Executive Director  5,000
     (Susan Searle)
     Purchase of Ordinary Shares at 194.83p per share for a PCA of a Non-Executive  5,000
     Director (Fraser Searle)
 d)  Aggregated information:

     Aggregated volume: n/a

     Aggregated price: n/a
 e)  Date of the transactions: 12/05/2025
 f)  Place of the transaction: London Stock Exchange (XLON)

d)

Aggregated information:

Aggregated volume: n/a

Aggregated price: n/a

e)

Date of the transactions: 12/05/2025

f)

Place of the transaction: London Stock Exchange (XLON)

 

 

 1.  Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name: Chris Meredith
 2.  Reason for the notification
 a)  Position/status: Chief Executive Officer
 b)  Initial notification/Amendment: Initial Notification
 3.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name:   Advanced Medical Solutions Group plc
 b)  LEI: 213800HJP6OWOSZI1L74
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument: Ordinary Shares
     of 5p

     Identification code: GB0004536594
 b)  Nature of the transactions:

     ·        Exercise of nil-cost LTIPs

     ·        Exercise of nil-cost ESPP Matching Shares

     ·        Sale of Ordinary Shares of 5p from the nil-cost LTIP and
     nil-cost ESPP

     ·        Purchase of Ordinary Shares as part of the SIP and ESPP on 12
     May 2025
 c)  Price(s) and volume(s):

Price(s)                                                       Volume(s)
     Exercise of nil-cost LTIPs                                     64,000
     Sale of shares from LTIP at 194.61p per share                  64,000
     Exercise of nil-cost LTIPs and nil- cost ESPP Matching Shares  421,728
     Sale of shares from LTIP and ESPP at 193.80p per share         211,521
     Purchase by SIP and ESPP at 195.04p per share                  33,091
 d)  Aggregated information:

     Aggregated volume: n/a

     Aggregated price: n/a
 e)  Date of the transactions: 12/05/2025
 f)  Place of the transaction: London Stock Exchange (XLON)

d)

Aggregated information:

Aggregated volume: n/a

Aggregated price: n/a

e)

Date of the transactions: 12/05/2025

f)

Place of the transaction: London Stock Exchange (XLON)

 

 

 1.  Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name: Eddie Johnson
 2.  Reason for the notification
 a)  Position/status: Chief Financial Officer
 b)  Initial notification/Amendment: Initial Notification
 3.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name:   Advanced Medical Solutions Group plc
 b)  LEI: 213800HJP6OWOSZI1L74
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument: Ordinary Shares
     of 5p

     Identification code: GB0004536594
 b)  Nature of the transactions:

     ·        Exercise of LTIPs

     ·        Exercise of ESPP Matching Shares

     ·        Exercise of Deferred Bonus Share

     ·        Sale of Ordinary Shares of 5p from the LTIP and ESPP

     ·        Purchase of Ordinary Shares as part of the SIP and ESPP on 12
     May 2025
 c)  Price(s) and volume(s):

Price(s)                                                                       Volume(s)
     Exercise of nil-cost LTIPs and nil-cost ESPP Matching Shares                   44,528
     Sale of shares from LTIP at 196.40p per share                                  28,126
     Sale of shares from ESPP at 194.62p per share                                  16,402
     Exercise of nil-cost LTIPs, nil- cost ESPP Matching Shares and Deferred Bonus  229,697
     Shares
     Sale of shares from LTIP, ESPP and Deferred Bonus at 194.62p per share         115,206
     Purchase by SIP and ESPP at 195.04p per share                                  21,592
 d)  Aggregated information:

     Aggregated volume: n/a

     Aggregated price: n/a
 e)  Date of the transactions: 12/05/2025 and 13/05/2025
 f)  Place of the transaction: London Stock Exchange (XLON)

d)

Aggregated information:

Aggregated volume: n/a

Aggregated price: n/a

e)

Date of the transactions: 12/05/2025 and 13/05/2025

f)

Place of the transaction: London Stock Exchange (XLON)

 

- Ends -

 

For further information, please visit www.admedsol.com
(http://www.admedsol.com) or contact:

 

 Advanced Medical Solutions Group plc     Tel: +44 (0) 1606 545508
 Chris Meredith, Chief Executive Officer

 Eddie Johnson, Chief Financial Officer

 Michael King, Investor Relations

 ICR Consilium                            Tel: +44 (0) 20 3709 5700
 Mary-Jane Elliott / Lucy Featherstone    AMS@consilium-comms.com

 Investec Bank PLC (NOMAD & Broker)       Tel: +44 (0) 20 7597 5970
 Gary Clarence / David Anderson

 HSBC Bank PLC (Broker)                   Tel: 44 (0) 20 7991 8888
 Joe Weaving / Stephanie Cornish

 

About Advanced Medical Solutions Group plc - see www.admedsol.com
(http://www.admedsol.com)

AMS is a world-leading independent developer and manufacturer of innovative
tissue-healing technology, focused on quality outcomes for patients and value
for payers. AMS has a wide range of surgical products including tissue
adhesives, sutures, haemostats, internal fixation devices and internal
sealants, which it markets under its brands LiquiBand®, RESORBA®,
LiquiBandFix8®, LIQUIFIX™, Peters Surgical, Ifabond, Vitalitec and
Seal-G®. AMS also supplies wound care dressings such as silver alginates,
alginates and foams through its ActivHeal® brand as well as under white
label. Since 2019, the Group has made seven acquisitions: Sealantis, an
Israeli developer of innovative internal sealants, Biomatlante, a French
developer and manufacturer of surgical biomaterials, Raleigh, a leading UK
coater and converter of woundcare and bio-diagnostics materials, AFS Medical,
an Austrian specialist surgical business, Connexicon, an Irish tissue
adhesives specialist, Syntacoll, a German specialist in collagen-based
absorbable surgical implants and Peters Surgical, a global provider of
specialty surgical sutures, mechanical haemostasis and internal cyanoacrylate
devices.

AMS's products, manufactured in the UK, Germany, France, the Netherlands,
Thailand, India, the Czech Republic and Israel, are sold globally via a
network of multinational or regional partners and distributors, as well as via
AMS's own direct sales forces in the UK, Germany, Austria, France, Poland,
Benelux, India, the Czech Republic and Russia. The Group has R&D
innovation hubs in the UK, Ireland, Germany, France and Israel. Established in
1991, the Group has more than 1,500 employees. For more information, please
see www.admedsol.com (http://www.admedsol.com) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBRGDUXDBDGUU